Andreas S.
- Country
- Germany
- Department
- Clinic for Internal Medicine, Gastroenterology
Research Overview
- A randomized, double-blind, multicenter phase III study to evaluate the long-term efficacy and safety of ABX464 25 mg or 50 mg once daily as a maintenance therapy in subjects with moderately to severely active ulcerative colitis
- Efficacy and Safety of Obefazimod (ABX464) in Adults with Moderately to Severely Active Ulcerative Colitis: A Randomized Placebo‑Controlled Phase III Study
- Long‑Term Safety and Efficacy of SPY001‑001 Monotherapy and Combination Therapy with Long‑Acting Antibodies in Adults with Ulcerative Colitis
Data & Insights
Has run more than one trial at 248 of 454 partner sites.
Specializations
Inflammatory Bowel Disease Management
This investigator specializes in the treatment of inflammatory bowel diseases, with particular focus on both Crohn's disease and ulcerative colitis in their moderate to severe forms.
- Therapeutic Assessment
- Disease Activity Monitoring
- Treatment Response Evaluation
The research encompasses various therapeutic approaches for managing inflammatory bowel conditions.
Novel Therapeutic Approaches
The investigator explores innovative treatment methods including targeted therapies and biological agents for gastrointestinal disorders.
- Biological Treatment Assessment
- Novel Drug Evaluation
- Long-term Therapeutic Outcomes
Expertise extends to evaluating emerging treatments for inflammatory bowel conditions.
Microbiome Research
Investigation into microbiota-based treatments and their therapeutic potential in gastrointestinal disorders.
- Microbiome Transfer Studies
- Gut Flora Analysis
- Treatment Innovation
Focus includes assessment of microbiome-based interventions in ulcerative colitis treatment.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.